This therapeutic concept targets the WAVE (Wiskott-Aldrich syndrome protein family verprolin-homologous protein) regulatory complex to restore actin cytoskeleton dynamics impaired in Alzheimer's disease, Parkinson's disease, ALS, and FTD. The WAVE complex (WASF1/WASF2/WASF3, CYFIP1/CYFIP2, ABI1/ABI2/ABI3, NAP1, HSPC300) is a critical effector of Rac1 signaling that controls actin polymerization through Arp2/3 activation.
- WAVE complex dysfunction in neurodegeneration: Multiple studies show WASF2 and CYFIP2 are downregulated in AD brain, leading to impaired actin dynamics in dendritic spines and synaptic loss[@han2022; @kim2013]
- Genetic evidence linking WAVE complex to neurodegeneration: CYFIP2 variants cause neurodevelopmental disorders; ABI3 variants are genetic risk factors for AD
- Converging point for multiple pathological pathways: Amyloid-beta, alpha-synuclein, and TDP-43 all disrupt WAVE complex signaling through distinct mechanisms
- Therapeutic window: Small molecule stabilizers or gene therapy can restore WAVE complex function without disrupting normal actin dynamics
- WAVE complex downregulation: WASF2 and CYFIP2 are significantly downregulated in AD hippocampus and prefrontal cortex
- Amyloid-beta effects: Aβ oligomers disrupt Rac1-WAVE-Arp2/3 signaling, causing dendritic spine loss and synaptic dysfunction[@kim2013]
- Therapeutic approach: WASF2 overexpression or small molecule stabilization restores spine density in AD models
- Dopaminergic neuron vulnerability: WAVE complex regulates actin dynamics critical for dopamine neuron viability and axonal transport
- Alpha-synuclein toxicity: α-syn oligomers disrupt WASF2 phosphorylation and actin polymerization
- Therapeutic approach: CYFIP2 stabilization protects against α-syn-induced cytoskeletal defects
- CYFIP2 in neuromuscular junction: CYFIP2 regulates actin cytoskeleton at the NMJ; loss-of-function affects synaptic stability
- TDP-43 pathology: TDP-43 aggregates disrupt WAVE complex mRNA processing
- Therapeutic approach: Restore WAVE complex expression via AAV-WASF2 delivery
- Cytoskeletal dysfunction: FTD brain shows WAVE complex alterations similar to ALS
- GRN deficiency: Progranulin loss affects WAVE complex regulation through undefined mechanisms
- Therapeutic approach: Combined progranulin restoration and WAVE complex enhancement
| Evidence Type |
Source |
Key Finding |
Relevance |
| WASF2 expression |
[Acta Neuropathol 2021, Available] |
WASF2 protein levels reduced in AD temporal cortex |
High |
| CYFIP2 genetics |
[Neurology 2020, Available] |
CYFIP2 variants in neurodevelopmental disorders |
Medium |
flowchart TD
A["Rac1 GTP"] --> B["WAVE Complex Recruitment"]
B --> C["WASF2/3 Activation"]
C --> D["Arp2/3 Complex"]
D --> E["Actin Branching/Nucleation"]
E --> F["Lamellipodia Formation"]
E --> G[" dendritic spine remodeling"]
F --> H["Axonal Growth/Regeneration"]
G --> I["Synaptic Plasticity"]
A1["Aβ oligomers"] -.->|Inhibit| B
A2["α-syn oligomers"] -.->|Disrupt| C
A3["TDP-43"] -.->|Impair| B
T1["Therapeutic Intervention"]
T1 --> T2["Small molecule WAVE stabilizers"]
T1 --> T3["AAV-WASF2 gene therapy"]
T1 --> T4["Rac1 activators"]
T2 -->|"Restore"| E
T3 -->|"Restore"| E
T4 -->|"Activate"| B
- Target: Stabilize WASF2-CYFIP2 interaction
- Lead compounds: Rac1 activators (e.g., small molecule mimics of active Rac1)
- Delivery: Oral or intranasal
- Challenges: Achieving CNS penetration
- Target: Overexpress WASF2 in neurons
- Vector: AAV9 or AAV-PHP.B
- Delivery: Intrathecal or intravenous with BBB-crossing capsid
- Advantages: Direct restoration of WAVE complex function
- Target: Upstream Rac1 activation to enhance WAVE complex recruitment
- Compounds: EHop-16 (Rac1 activator), CNP (cGMP pathway)
- Delivery: Small molecules with established CNS penetration
- Synergy: Combines with direct WAVE enhancement
- WAVE + Synaptic plasticity: Combine with BDNF or NMDA modulators
- WAVE + Neuroinflammation: Combine with microglia-targeting approaches (TREM2, CX3CR1)
| Dimension |
Score |
Rationale |
| Novelty |
7 |
New therapeutic target (not yet in clinical trials for neurodegeneration) |
| Mechanistic Rationale |
9 |
Strong preclinical evidence linking WAVE complex to multiple neurodegenerative pathways |
| Root-Cause Coverage |
8 |
Addresses cytoskeletal dysfunction, a fundamental early event in neurodegeneration |
| Delivery Feasibility |
6 |
Gene therapy achievable; small molecules require CNS penetration optimization |
| Safety Plausibility |
8 |
WAVE complex modulation avoids complete actin disruption; physiological pathway |
| Combinability |
8 |
Highly synergistic with synaptic plasticity, neuroprotection, and anti-aggregation approaches |
| Biomarker Availability |
6 |
WASF2/CYFIP2 expression measurable in postmortem brain; CSF biomarkers under development |
| De-risking Path |
7 |
Can start with AAV-WASF2 in non-human primates, then progress to IND-enabling studies |
| Multi-disease Potential |
9 |
Strong rationale for AD, PD, ALS, FTD, and aging-related cognitive decline |
| Patient Impact |
8 |
Addresses fundamental cytoskeletal defect affecting neuronal connectivity and survival |
| Total |
76 |
|
- Validate WAVE complex dysfunction in patient-derived iPSC neurons
- Test AAV-WASF2 delivery in mouse models of AD/PD
- Optimize small molecule WAVE stabilizers for CNS penetration
- GLP toxicology for lead AAV-WASF2 construct
- Biodistribution studies in non-human primates
- FDA pre-IND meeting
- Phase 1 safety in healthy volunteers (gene therapy)
- Phase 2 efficacy in early AD or PD patients
- Biomarker development for patient selection
- Validate target: Quantify WASF2, CYFIP2 levels in AD/PD patient brain and iPSC-derived neurons
- Develop biomarkers: Establish CSF or blood biomarkers for WAVE complex activity
- Lead optimization: Screen for small molecule WAVE complex stabilizers with CNS penetration
- Gene therapy vector: Test AAV serotypes for efficient neuronal transduction of WASF2